Study guide
17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy
WHNP-BC Women's Health Nurse Practitioner Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: About the WHNP-BC Exam
WHNP-BC Exam Facts, Blueprint & Study Plan
2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening
1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening
3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention
2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites
4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers
3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers
5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility
4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies
6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy
5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion
7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health
6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis
8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care
7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction
9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care
8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy
10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth
9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency
11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions
10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn
12 Chapter 11: Intrapartum Principles & Fetal Surveillance
11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies
13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications
12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs
14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions
13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold
15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders
14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders
16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health
15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis
17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care
16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care
18 Chapter 17: Assessment, Diagnostic Testing & Interpretation
17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities
19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing
18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation
20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities
19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care
17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy
Key Takeaways Explain This Topic AI
Point-of-care vaginal microscopy provides rapid diagnostic discrimination among bacterial vaginosis (clue cells >20%, absent lactobacilli, few leukocytes), vulvovaginal candidiasis (pseudohyphae and budding blastospores on 10% KOH), and trichomoniasis (motile flagellated trichomonads with elevated WBC:epithelial cell ratio >1:1).
The 10% potassium hydroxide (KOH) amine whiff test releases volatile polyamines (putrescine, cadaverine) upon alkalinization, yielding a pungent fishy odor characteristic of bacterial vaginosis and trichomoniasis, while remaining negative in vulvovaginal candidiasis.
Endometrial biopsy (EMB) is indicated in women aged ≥45 presenting with abnormal uterine bleeding (AUB), in women <45 with chronic unopposed estrogen (obesity, PCOS, tamoxifen, Lynch syndrome), and in postmenopausal women with bleeding and an endometrial stripe >4 mm on transvaginal ultrasound.
Colposcopic assessment utilizes 3–5% acetic acid to induce reversible nuclear protein dehydration (acetowhite changes) and Lugol's iodine (Schiller test) to highlight glycogen-depleted dysplasia, with vascular patterns (fine vs. coarse punctation, mosaicism, and bizarre atypical vessels) directing biopsy placement.
Endocervical curettage (ECC) is mandatory when the squamocolumnar junction / transformation zone is not fully visualized (Type 3 TZ) or following atypical glandular cells (AGC) cytology, but ECC is strictly contraindicated during pregnancy due to risks of membrane rupture and severe hemorrhage.
Last updated: October 2026
Point-of-Care Vaginal Microscopy & Diagnostic Evaluation
Point-of-care microscopic evaluation of vaginal secretions provides rapid, real-time diagnostic differentiation among the primary etiologies of vaginitis: bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and trichomoniasis.
Specimen Collection & Slide Preparation
Accurate diagnostic microscopy depends on meticulous specimen collection:
Collection Technique: Sample secretions from the lateral vaginal walls and posterior fornix using a sterile Dacron or cotton-tipped swab. Clinicians must avoid collecting cervical mucus; endocervical secretions are physiologically alkaline (pH > 7.0) and harbor abundant leukocytes, which falsely elevate vaginal pH readings and distort cell ratios. Lubricants must not be applied to the speculum prior to sampling, as commercial gels lyse trichomonads and cause cellular artifact.
Saline Wet Mount Preparation: Disperse a drop of vaginal discharge into 1 to 2 drops of 0.9% normal saline on a glass slide, applying a coverslip gently. Examine immediately under low power (10×) and high-dry power (40×).
10% Potassium Hydroxide (KOH) Mount: Emulsify a second aliquot in 1 to 2 drops of 10% KOH solution. Potassium hydroxide rapidly dissolves host cellular membranes, lysing squamous cells, erythrocytes, and leukocytes. This clears obscuring background debris to highlight the chitinous cell walls of branching pseudohyphae and budding yeast spores (blastospores) of Candida albicans (non-albicans such as C. glabrata produce budding blastospores without pseudohyphae).
The Amine Whiff Test: Immediately upon adding 10% KOH, assess for the volatilization of aromatic amines (putrescine, cadaverine, trimethylamine) produced by anaerobic decarboxylation. A pungent, "fishy" odor constitutes a positive whiff test, characteristic of BV and frequently trichomoniasis, but absent in candidiasis.
Microscopic Findings & Differential Matrix
Diagnostic Parameter Normal Vaginal State Bacterial Vaginosis (BV) Vulvovaginal Candidiasis (VVC) Trichomoniasis
Predominant Flora Lactobacillus species Gardnerella , Atopobium , anaerobes Candida albicans (85–90%), C. glabrata Trichomonas vaginalis (flagellated protozoan)
- Vaginal pH 3.8 to 4.5 >4.5 (typically 5.0 to 5.5) 3.8 to 4.5 (acidic) >4.5 (frequently 5.5 to 6.5)
- Amine Whiff Test Negative Strongly positive Negative Often positive
Saline Microscopy Mature squames, healthy lactobacilli Clue cells (≥20%), sparse lactobacilli Budding yeast, blastospores Motile flagellated trichomonads
WBC:Epithelial Ratio <1:1 (sparse leukocytes) <1:1 (non-inflammatory) Variable; often mild WBCs >1:1 (dense polymorphonuclear WBCs)
10% KOH Microscopy Dissolved debris Dissolved debris Branching pseudohyphae & blastospores Lysis of trichomonads
Important
Evaluating Clue Cells & Inflammation: Clue cells are squamous epithelial cells whose borders are obscured by adherent coccobacilli, giving the cytoplasm a granular appearance. Under Amsel criteria, clue cells must constitute at least 20% of visualized squamous cells to establish a diagnosis of BV. Because uncomplicated BV is a non-inflammatory dysbiosis, the WBC:epithelial cell ratio remains <1:1. The presence of marked inflammation (ratio >1:1) flags concurrent trichomoniasis, cervicitis ( C. trachomatis or N. gonorrhoeae ), or desquamative inflammatory vaginitis.
Endometrial Biopsy (EMB): Indications, Technique & Histopathology
Endometrial aspiration biopsy (EMB) is the primary diagnostic office procedure used to evaluate abnormal uterine bleeding and detect endometrial hyperplasia or adenocarcinoma.
Clinical Indications
AUB in Females Aged ≥45 Years: Any abnormal bleeding in women aged 45 and older warrants first-line EMB.
AUB in Females Aged <45 Years with Risk Factors: Persistent bleeding in women under 45 with chronic unopposed estrogen exposure: obesity (BMI ≥30 kg/m²), polycystic ovary syndrome (PCOS), chronic anovulation, tamoxifen therapy, Lynch syndrome, or medical therapy failure.
Postmenopausal Bleeding (PMB): Any spontaneous bleeding occurring ≥12 months after menopause requires transvaginal ultrasonography (TVUS). An endometrial stripe >4 mm , or a heterogeneous, focal, or vascular stripe, mandates EMB. Recurrent bleeding warrants biopsy regardless of stripe thickness.
Atypical Glandular Cells (AGC) Cytology: Women aged ≥35 years (or <35 with risk factors) require concurrent colposcopy and EMB.
Technique, Complications & Histopathology
Technique: Perform a bimanual exam to confirm uterine size and orientation. Cleanse the ectocervix with povidone-iodine. Apply a single-tooth tenaculum to the anterior cervical lip for gentle countertraction. Advance a flexible 3.1 mm Pipelle cannula into the uterine cavity to fundal resistance (depth 6–8 cm). Withdraw the internal piston to generate suction, rotate 360 degrees, and move between fundus and internal os across all uterine walls before placing tissue into formalin.
Complications: Uterine cramping (mitigated by pre-procedure ibuprofen 600–800 mg PO); vasovagal syncope (release tenaculum, Trendelenburg position, cool compress); pelvic infection (<1%); and uterine perforation (loss of resistance, sharp pain; abort procedure, monitor vital signs, perform serial hematocrits, and obtain laparoscopy if unstable).
Histologic Findings: Proliferative (estrogen-driven follicular phase), Secretory (post-ovulatory progesterone-driven luteal phase), Atrophic (thin, resting glands; normal postmenopausal), Endometrial hyperplasia without atypia (glandular crowding, 1–3% cancer risk; treated with progestins like LNG-52mg IUD), Endometrial hyperplasia with atypia / EIN (cytologic atypia, 30–40% risk of concurrent adenocarcinoma ; total hysterectomy preferred), and Endometrial adenocarcinoma (malignant stromal invasion; urgent oncology referral).
Colposcopy: Optics, Dynamic Testing & Biopsy Principles
Colposcopy enables magnified (6× to 40×) stereoscopic examination of the lower genital tract to direct biopsies of suspected cervical intraepithelial neoplasia (CIN).
Optical Filters & Dynamic Testing
Green Optical Filter: Absorbs red light, causing subepithelial capillaries to appear dark against a light background, accentuating abnormal vascular architecture.
3% to 5% Acetic Acid Application: Dehydrates cells and reversibly coagulates nuclear proteins. Dysplastic cells with dense nuclear crowding reflect light, producing distinct acetowhite changes .
Lugol's Iodine Solution (Schiller Test): Iodine reacts with glycogen in mature squamous cells, staining normal tissue dark mahogany brown. Glycogen-depleted dysplastic epithelium, invasive cancer, or columnar cells remain yellow or unstained ("Schiller-positive" / iodine-negative).
Transformation Zone (TZ) Classification & Vascular Abnormalities
Type 1 TZ: Completely visible and entirely ectocervical.
Type 2 TZ: Completely visible with an endocervical component.
Type 3 TZ: Endocervical component is not completely visible (recedes into the canal); classified as "inadequate" or "unsatisfactory".
Colposcopic Findings: Minor abnormalities include fine punctation and fine mosaicism. Major abnormalities include dense, chalky acetowhite epithelium, coarse punctation, coarse mosaicism, and rolled margins. Atypical vessels (hairpin, corkscrew, or branching vessels with irregular caliber) signal invasive carcinoma.
Important
Endocervical Curettage (ECC) & Pregnancy Contraindication: Directed punch biopsies are obtained from the most severe lesions (2 to 4 biopsies increase sensitivity for CIN 2/3+). Endocervical curettage (ECC) with a Kevorkian curette is mandatory if the TZ is Type 3, in AGC Pap smears, or if no ectocervical lesion explains high-grade cytology. However, ECC IS STRICTLY CONTRAINDICATED IN PREGNANCY due to risks of membrane rupture, severe hemorrhage, and chorioamnionitis.
Cervical Polypectomy
Endocervical polyps are benign vascular mucosal growths causing contact spotting or leukorrhea. Remove by grasping the pedicle with polyp forceps and twisting 360 degrees until avulsion occurs. Achieve hemostasis with silver nitrate or Monsel's solution (ferric subsulfate). Every polyp must be submitted in formalin for histopathology to exclude rare adenocarcinoma.